New supplement shows promise for appetite control in early study
NCT ID NCT06790771
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a dietary supplement containing L-arginine, resveratrol, tart cherry, and vitamin C can reduce hunger and increase a hormone called GLP-1, which helps control appetite and blood sugar. Twenty-five adults with overweight or obesity took part in three lab visits, each time receiving either a high or low dose of the supplement or a placebo. Researchers measured GLP-1 levels and hunger ratings over two hours. The goal is to see if this supplement could become a helpful tool for weight loss.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
25 people
The number who actually took part.
- Started
-
Jan 2025
- Finished
-
Mar 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Participants must meet all the following conditions to be eligible for the study: * Age: 18-60 years old. * BMI (Body Mass Index): Between 25 and 40 kg/m². * Diet and Activity Stability: Willing to maintain current dietary and physical activity habits for the duration of the study. Exclusion Criteria: Participants will be excluded from the study if any of the following conditions apply: * Recent Weight Change: Lost or gained more than 5% of body weight in the last 3 months. * Pregnancy or Lactation: Pregnant or breastfeeding women. * Medical Conditions: * Kidney disease (Chronic Kidney Disease or End-Stage Renal Disease). * Herpes simplex. * Uncontrolled diabetes (HbA1c \>7%). * Thyroid disorders or taking thyroid medications. * Type 1 diabetes. * Cushing syndrome. * Cirrhosis or hepatitis. * Chronic obstructive pulmonary disease (COPD). * Dementias. * Active autoimmune diseases (e.g., lupus, rheumatoid arthritis). * Crohn's disease or ulcerative colitis. * Celiac disease. * Allergies or Sensitivities: * Known allergies to any components of the supplement or standardized meal. * Medications: Currently taking any of the following: * Supplements or medications for weight loss. * Antihypertensive, antidiabetic, or antihyperlipidemic medications. * Erectile dysfunction medications. * Blood thinners (e.g., aspirin, warfarin). * Medications containing nitric oxide or nitroglycerin. * Drugs affecting GLP-1 levels, such as GLP-1 receptor agonists, insulin, certain antidepressants, or corticosteroids. * Substance Use: Evidence of illegal drug use, including marijuana. * Participation in Other Studies: Enrollment in another clinical trial that could interfere with the study outcomes.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUNGER are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Texas Christian University
Fort Worth, Texas, 76129, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.